A bifunctional fusion protein and its use in treating retinal degenerative diseases

CN122103370APending Publication Date: 2026-05-29YUYAO PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
YUYAO PEOPLES HOSPITAL
Filing Date
2026-03-05
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Current strategies for treating retinal degenerative diseases mainly target pathological angiogenesis or neurotrophic factors alone, which cannot effectively prevent nerve cell degeneration, and the application of existing drugs such as anti-VEGF drugs and neurotrophic factors is limited.

Method used

Design a bifunctional fusion protein comprising an anti-VEGF antibody and a BDNF moiety, which are linked by a linker to achieve synergistic effects, inhibiting the VEGF pathway and providing neurotrophic support.

Benefits of technology

It significantly improved electroretinogram amplitude in the rd10 mouse model, reflecting the recovery of cone function. The effect was significantly better than that of single drugs, and the protein expression and purification process was mature and suitable for large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122103370A_ABST
    Figure CN122103370A_ABST
Patent Text Reader

Abstract

The application relates to the technical field of biological medicine, and particularly discloses a bifunctional fusion protein and application thereof in treating retinal degenerative diseases. The fusion protein is named Beva-1L, which is formed by fusing an amino acid sequence of human brain-derived neurotrophic factor (BDNF) with a light chain of an anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab. The fusion protein can simultaneously inhibit VEGF-mediated pathological angiogenesis and provide neurotrophic support, and is used for treating retinal degenerative diseases such as diseases simulated by an rd10 mouse model. Experiments show that the amplitude of a retinal electrogram (ERG) of the rd10 mouse can be significantly improved by injecting the Beva-1L, and the effect is equivalent to that of a positive drug. The application also relates to a coding gene, an expression vector, a host cell, a pharmaceutical composition of the fusion protein and application thereof. The fusion protein has a bifunctional synergistic effect, and provides a new treatment strategy for retinal degenerative diseases.
Need to check novelty before this filing date? Find Prior Art